Sae-Won Han
Department
Hemato Oncology
Medical Oncology Center
Specialty
Appointment
Colorectal cancer (colon cancer, rectal cancer)
Colorectal cancer (colon cancer, rectal cancer)
,
Clinical trial
,
Personalized treatment
Education / Career
| Article | Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer | ||
|---|---|---|---|
| Announcements | PLoS One | Date of publication | 2012.07 |
| Co-researcher | Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY. | ||
| Article | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer | ||
|---|---|---|---|
| Announcements | Int J Cancer | Date of publication | 2013.05 |
| Co-researcher | Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY. | ||
| Article | Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy | ||
|---|---|---|---|
| Announcements | Br J Cancer | Date of publication | 2013.05 |
| Co-researcher | Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY. | ||
| Article | Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing | ||
|---|---|---|---|
| Announcements | PLoS One | Date of publication | 2013.05 |
| Co-researcher | Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY. | ||
| Article | RNA editing in RHOQ promotes invasion potential in colorectal cancer | ||
|---|---|---|---|
| Announcements | J Exp Med | Date of publication | 2014.04 |
| Co-researcher | Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Kim KY, Park SY, Lee DW, Won JK, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY. | ||
| Article | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX | ||
|---|---|---|---|
| Announcements | Ann Surg Oncol | Date of publication | 2015 Jan |
| Co-researcher | Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY. | ||
| Article | Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. | ||
|---|---|---|---|
| Announcements | Mol Cancer Ther | Date of publication | 2009 Sep |
| Co-researcher | Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, Kim TY. | ||
| Article | Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. | ||
|---|---|---|---|
| Announcements | Cancer Sci | Date of publication | 2009 Nov |
| Co-researcher | Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY | ||
| Article | Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. | ||
|---|---|---|---|
| Announcements | PLoS One | Date of publication | 2009 Jun |
| Co-researcher | Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY. | ||
| Article | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. | ||
|---|---|---|---|
| Announcements | Br J Cancer | Date of publication | 2009 Jan |
| Co-researcher | Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. | ||
| Article | The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. | ||
|---|---|---|---|
| Announcements | BMC Cancer | Date of publication | 2008 Oct |
| Co-researcher | Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY. | ||
| Article | Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. | ||
|---|---|---|---|
| Announcements | BMC Cancer | Date of publication | 2008 May |
| Co-researcher | Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ | ||
| Article | "Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. | ||
|---|---|---|---|
| Announcements | Mol Cancer Ther | Date of publication | 2008 Mar |
| Co-researcher | Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, Kim TY. | ||
| Article | Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. | ||
|---|---|---|---|
| Announcements | Lung Cancer | Date of publication | 2008 Jul |
| Co-researcher | Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. | ||
| Article | "Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. | ||
|---|---|---|---|
| Announcements | Expert Rev Mol Diagn | Date of publication | 2007 Nov |
| Co-researcher | Kim TY, Han SW, Bang YJ. | ||
| Article | Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. | ||
|---|---|---|---|
| Announcements | Lung Cancer | Date of publication | 2006 Nov |
| Co-researcher | Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ. | ||
| Article | Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. | ||
|---|---|---|---|
| Announcements | Clin Cancer Res | Date of publication | 2006 Apr |
| Co-researcher | Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. | ||
| Article | Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. | ||
|---|---|---|---|
| Announcements | J Clin Oncol | Date of publication | 2005 Apr |
| Co-researcher | Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. | ||
| Article | "Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. | ||
|---|---|---|---|
| Announcements | Int J Cancer | Date of publication | 2005 Jan |
| Co-researcher | Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK. | ||
| Article | Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. | ||
|---|---|---|---|
| Announcements | Pharmacogenet Genomics | Date of publication | 2007 May |
| Co-researcher | Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. | ||